Drug intelligence / Profile preview

oxaliplatin + S-1 + tislelizumab

Development stage: Unknown
Lead developer: Union Hospital of Huazhong University of Science and Technology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Intraperitoneal

Overview

This therapeutic regimen is a combination of hyperthermic intraperitoneal chemotherapy (HIPEC) using oxaliplatin, systemic SOX chemotherapy (comprising oxaliplatin and S-1), and the immune checkpoint inhibitor tislelizumab. It is being investigated by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology for the treatment of gastric cancer with peritoneal metastasis. The approach aims to improve R0 resection rates and survival outcomes by combining local regional control through heated intraperitoneal chemotherapy, systemic cytotoxic effects from the SOX regimen, and immune-mediated anti-tumor activity via PD-1 blockade with tislelizumab. Oxaliplatin acts as a DNA cross-linking agent, S-1 is a multi-component fluoropyrimidine that inhibits thymidylate synthase, and tislelizumab is a humanized monoclonal antibody that enhances T-cell mediated immunity.

Other names: HIPEC + SOX + TislelizumabHyperthermic Intraperitoneal Chemotherapy with SOX and Tislelizumab

Targets

TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)DNA

Beyond the preview

Go deeper on oxaliplatin + S-1 + tislelizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxaliplatin + S-1 + tislelizumab.

Explore the full profile